Table 2.

Causes of omalizumab discontinuation at t − 1 and t − 2

Causes	t − 1 n (%)	t − 2 n (%)
Administrative barriers/health insurance company did not authorize	3 (37.5)	1 (6.67)
Adverse event	3 (37.5)	3 (20)
Worsening of symptoms/therapy change	1 (12.5)	–
Suspended by -pulmonologist decision (no explicit reason)	1 (12.5)	–
Suspended by allergologist decision (no explicit reason)	–	3 (20)
Distant home	–	2 (13.3)
Asthma exacerbation	–	1 (6.7)
Diagnosis and treatment of cancer	–	1 (6.7)
Weight gain	–	1 (6.7)
No response to treatment	–	1 (6.7)
Persistency of shortness of breath and wheezing	–	1 (6.7)
Improvement and the need of provocation tests	–	1 (6.7)